Results 171 to 180 of about 13,346 (214)

Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma. [PDF]

open access: yesSci Transl Med
Giudice AM   +20 more
europepmc   +1 more source

Exploring the long-term use of ambroxol in Gaucher disease type 2: insights from two pediatric cases. [PDF]

open access: yesFront Neurol
Aries C   +7 more
europepmc   +1 more source

BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells. [PDF]

open access: yesNat Immunol
Hu T   +8 more
europepmc   +1 more source

Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy

open access: yesPediatric and Developmental Pathology, 2017
Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with an immunotherapy based on a chimeric monoclonal antibody ch14.18.
Tatjana, Terzic   +8 more
openaire   +3 more sources
Some of the next articles are maybe not open access.

Related searches:

Disialoganglioside GD2 as a therapeutic target for human diseases

Expert Opinion on Therapeutic Targets, 2015
Ganglioside GD2 is found in vertebrates and invertebrates, overexpressed among pediatric and adult solid tumors, including neuroblastoma, glioma, retinoblastoma, Ewing's family of tumors, rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, small cell lung cancer and melanoma.
Maya Suzuki
exaly   +3 more sources

Home - About - Disclaimer - Privacy